Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with ...

Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for ...

You don’t have to feel fully ready to start trauma therapy. Waiting may be what’s keeping symptoms stuck in place, and it ...

The early results from a phase II study on the use of the topotecan episcleral chemoplaque (Targeted Therapy Technologies LLC ...

IDEAYA Biosciences and Servier have reported positive top line results from the Phase II/III registration trial, OptimUM-02, ...

Under two different Illinois laws, people charged with sex offenses are subject to indefinite detention. Some people who’ve ...

Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS ...

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies ...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria. Approval in CSU for children two to ...

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today announced positive ...

New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease controlAXPAXLI ...